[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"familial-pancreatic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:familial-pancreatic-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100574550","prevenpanc-project-a-spanish-multicenter-study-for-pancreatic-cancer-prevention-100574550",false,"NCT06760741","PREVENPANC Project: a Spanish Multicenter Study for Pancreatic Cancer Prevention","PREVENPANC","Inclusion Criteria:\n\n* Patients with a recent diagnosis of pancreatic cancer in the general population.\n* High-risk individuals under follow-up in high-risk clinics (hereditary syndromes, familial pancreatic cancer).\n\nExclusion Criteria:\n\n* Patients under 18 years old.\n* Patients who have undergone treatment for pancreatic cancer.",true,"ALL","18 Years",{"count":20,"type":21},900,"ESTIMATED","OBSERVATIONAL","Background: Pancreatic cancer (PC) is an aggressive cancer with only a 7% 5-year survival rate, primarily due to late-stage diagnosis. In Spain, its incidence is rising, and by 2030, it is expected to become the second leading cause of cancer-related death worldwide. Approximately 3% of PCs occur in the context of hereditary pancreatic cancer (HPC) predisposition syndromes. Studies have shown that up to 40% of genetic mutations associated with PC in individuals under 60 years old would not have been identified using traditional clinical criteria for genetic testing. Presymptomatic genetic testing is recommended for relatives of patients with hereditary syndromes to identify those at higher risk of PC and to include them in screening programs to alter the natural history of the disease. However, there is no robust evidence supporting the best tool for early diagnosis in at-risk individuals. Currently, screening relies on endoscopic ultrasound or magnetic resonance imaging, which yield suboptimal results.\n\nAims: By studying the clinical, molecular, and genetic characteristics of PC patients and their families, this project aims to identify factors conferring higher PC risk and to adopt preventive measures while evaluating the efficacy of current screening strategies. Additionally, the project includes a traslational subproject to identify new hereditary genes associated with increased PC risk and novel molecules (biomarkers, specifically miRNAs) with diagnostic potential. These biomarkers could serve as non-invasive tools to identify individuals at increased risk of PC through blood tests, enabling preventive measures or early diagnosis.\n\nGiven the low incidence of PC (albeit with high mortality), collaborative studies are essential to achieve meaningful results. The current project represents the first Spanish multicenter population-based registry for PC, integrating clinical data and biological sample collection alongside a control group. Its goal is to prevent PC and foster collaboration between basic research and clinical application in Spain within a proven collaborative framework.\n\nEstablishing the best strategy to detect high-risk individuals for PC within the general population.\n\nIdentifying new PC risk genes to expand the identification of at-risk individuals.\n\nDetermining effective prevention strategies for high-risk individuals. Creating a national network, \"PREVENPANC,\" for collaborative PC research, including the collection of biological samples (blood) from all enrolled patients.",[25,26,27],"Pancreatic Cancer, Adult","Hereditary Pancreatic Cancer","Familial Pancreatic Cancer",[29,30,31,32,33,34],"Screening","Pancreatic cancer","High risk pancreatic cancer","Hereditary pancreatic cancer","Familial pancreatic cancer","miRNA pancreatic cancer","NOT_YET_RECRUITING","2025-01-03",{"date":38,"type":39},"2025-01-07","ACTUAL",{"date":41,"type":21},"2025-01",{"date":43,"type":21},"2026-12",{"name":45,"class":46},"Hospital Clinic of Barcelona","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":59,"conditions":60,"keywords":66,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100419573","artificial-intelligence-based-early-screening-of-pancreatic-cancer-and-high-risk-tracing-esprit-ai-100419573","NCT04743479","Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)","Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer","ESPRIT-AI","Inclusion Criteria:\n\n* Subject is able and willing to provide informed consent and sign an informed consent form.\n* Subject or authorized representative must be willing to complete a detailed questionnaire.\n* Subject must meet one of the following criteria:\n\n  1. New onset diabetes (diagnosed within the past 3 years)\n  2. Familial pancreatic cancer\n  3. Inherited syndromes associated with pancreatic cancer (including Hereditary pancreatitis, Familial atypical multiple mole and melanoma syndrome, Hereditary nonpolyposis colon cancer, Peutz-Jeghers syndrome, Hereditary breast and ovarian cancer syndromes, etc)\n  4. Pancreatic cystic neoplasm (including IPMN, MCN)\n  5. Chronic pancreatitis\n\nExclusion Criteria:\n\n* Subject has been diagnosed with pancreatic cancer or other malignant tumors in the last 5 years;\n* Subject has any medical condition that contraindicates high-resolution MRI or CT;\n* Subject cannot be followed up or is participating in other clinical trials.","50 Years","75 Years",{"count":58,"type":21},5000,"Pancreatic cancer is one of the most fatal malignancies with a 5-year survival rate of only \\~6%\\[1\\]. The reasons for this high mortality rate can be attributed to several factors, of which perhaps the most important is delayed diagnosis due to vague symptoms and consequently missed opportunities for surgical resection. Therefore, the ability to detect pancreatic cancer at an early, more curable stage is urgently needed.\n\nIdentifying risk factors and biomarkers of early pancreatic cancer could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. Thus, the investigators propose this longitudinal study entitled, \"Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)\" in order to generate clinical data sets and bank serial blood specimens of high risk individuals.",[61,62,27,63,64,65],"Pancreatic Cancer","Diabetes","Pancreatic Cystic Neoplasm","Chronic Pancreatitis","Hereditary Pancreatitis",[29,67,68,61],"Early Diagnosis","Artificial Intelligence","RECRUITING","2023-08-31",{"date":72,"type":39},"2023-09-01",{"date":74,"type":39},"2020-12-01",{"date":76,"type":21},"2030-12-30",{"name":78,"class":46},"Changhai Hospital",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100369811","registry-of-subjects-at-risk-of-pancreatic-cancer-100369811","NCT04095195","Registry of Subjects at Risk of Pancreatic Cancer","Italian Registry of Families At Risk of Pancreatic Cancer","IRFARPC","Inclusion Criteria to enter the registry:\n\n* individuals with at least two relatives suffering from pancreatic cancer, with at least 1 first-degree and until the third-degree\n* subjects with known genetic mutation of BRCA2, BRCA1, p16, PALB2 with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer\n* subjects suffering from FAMMM Syndrome\n* subjects suffering from Peutz-Jeghers Syndrome\n* subjects suffering from PRSS-1- or CFTR- or SPINK-1- related pancreatitis\n* subjects suffering from Lynch syndrome with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer\n\nInclusion criteria to join the \"radiologic follow-up\":\n\n* 45 years or 10 years younger than the youngest index case of pancreatic cancer in the family for familial cases\n* 40 years or 5 years younger than the youngest index case of pancreatic cancer for subjects suffering from hereditary\u002Fgenetic pancreatitis, Lynch syndrome, or carrying a known BRCA 1\u002F2, PALB2, p16 genetic mutation with familiarity for pancreatic cancer\n* 30 years for subjects suffering from FAMMM, Peutz-Jeghers syndrome\n\nExclusion Criteria:\n\n\\- pregnancy","80 Years",{"count":90,"type":21},1000,"IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.",[27,93,94,95,96,65,97],"BRCA1 Mutation","BRCA2 Mutation","Lynch Syndrome","FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome","Peutz-Jeghers Syndrome",[27,99,95,100,101],"BRCA Mutation","Screening pancreatic cancer","Surveillance pancreatic cancer","2023-01-12",{"date":104,"type":39},"2023-01-13",{"date":106,"type":39},"2019-08-20",{"date":108,"type":21},"2045-09-20",{"name":110,"class":46},"Associazione Italiana per lo Studio del Pancreas",4]